Last reviewed · How we verify
NCT07380698: DOSTCONICG
The Effect of Dose and Storage Conditions of Indocyanine Green on Efficacy and Cost in Sentinel Lymph Node Mapping in Gynecological Cancer
trial in Endometrial Cancer in 30 participants. Currently enrolling.
3 August 2026
Quick facts
| Lead sponsor | Cukurova University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 30 |
| Start date | 3 October 2025 |
| Primary completion | 3 August 2026 |
| Estimated completion | 3 September 2026 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Endometrial Cancer — all drugs for Endometrial Cancer →
- Vulvar Cancers — all drugs for Vulvar Cancers →
- Cervical Cancer — all drugs for Cervical Cancer →
- Indocyanine Green (ICG) — all drugs for Indocyanine Green (ICG) →
Sponsor
Cukurova University
Who can join
Eligibility, female only, with Endometrial Cancer or Vulvar Cancers. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This research will determine the impact of optimizing dosage and storage conditions for indocyanine green on health outcomes and will contribute to improving treatment processes in gynecological cancers. Ultrastaging will increase the detection of micrometastases. Furthermore, the cost impact of these optimizations will be evaluated. It will help develop more effective, safe, and cost-effective methods for sentinel lymph node mapping in gynecological cancers. Furthermore, significant savings in healthcare costs could be achieved.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07380698
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Endometrial Cancer
Currently open trials in the same condition.
- NCT07419841 — A Phase 1 Study of the Safety and Tolerability of CTX-10726 · Phase 1 · recruiting
- NCT07382583 — Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the P · recruiting
- NCT07377734 — Intrauterine Injection of Type III Collage in FST of EC/AEH · Phase 2 · recruiting
- NCT07319429 — Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification · Phase 2, PHASE3 · recruiting
- NCT07397624 — Endoscopic Suture Gastroplasty (ESG) for Treatment of Obese Patients With Endometrial Cancer · recruiting
Other Cukurova University trials
Trials by the same sponsor.
- NCT07464652 — Objectıve Structured Clınıcal Examınatıon Stress For Intravenous Perıpheral Catheterızatıon · NA · not yet recruiting
- NCT07458789 — Breastfeeding Education · NA · not yet recruiting
- NCT07346482 — Determining the Effect of Midwife-Led Safe Infant Care Training for Pregnant Women on Awareness of Sudden Infant Death S · NA · not yet recruiting
- NCT07248904 — The Effect of a Transtheoretical Model-Based Educational Intervention on First-Year Nursing Students' HPV Knowledge, Hea · NA · recruiting
- NCT07241949 — Regional Analgesia Techniques for Laparoscopic Cholecystectomy · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07380698 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Cukurova University
- Last refreshed: 2 February 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07380698.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing